Home › Calculator › LCTX Dividend Calculator 2026
LCTX Dividend DRIP Calculator 2026
148.15% YieldHealthcareLineage Cell Therapeutics, Inc. · AMEX
Price: $1.35 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When LCTX pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your LCTX snowball 📈
$10,000 in LCTX → $34.60M in 10 years · $4,165.66/month
About Lineage Cell Therapeutics, Inc. (LCTX) — Dividend Analysis 2026
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Compare LCTX with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full LCTX DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open LCTX position with:
🌍 LCTX Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold LCTX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 148.15% | 145.35% | $14,815 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 125.93% | 123.13% | $12,593 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 118.52% | 115.72% | $11,852 / yr |
| 🇬🇧 UK ISA | 0% | 148.15% | 145.35% | $14,815 / yr |
| 🇬🇧 UK Taxable | 8.75% | 135.19% | 132.39% | $13,519 / yr |
| 🇨🇦 TFSA | 0% | 148.15% | 145.35% | $14,815 / yr |
| 🇨🇦 CA Taxable | 25% | 111.11% | 108.31% | $11,111 / yr |
| 🇦🇺 Super (pension) | 15% | 125.93% | 123.13% | $12,593 / yr |
| 🇦🇺 AU Taxable | 30% | 103.70% | 100.91% | $10,371 / yr |
| 🇩🇪 DE Taxable | 26.375% | 109.08% | 106.28% | $10,908 / yr |
| 🇫🇷 FR Taxable | 30% | 103.70% | 100.91% | $10,371 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 LCTX Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 LCTX Dividend Payment Schedule
LCTX pays quarterly — 4 times per year. Next ex-div: TBD.
📊 LCTX vs Healthcare Benchmarks
How LCTX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for LCTX sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ LCTX Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-07-01 | 125,000 | $1.30 | $162.5K | ||
| A-Award | 2026-07-01 | 125,000 | $1.30 | $162.5K | ||
| A-Award | 2026-07-01 | 125,000 | $1.30 | $162.5K | ||
| A-Award | 2026-07-01 | 125,000 | $1.30 | $162.5K | ||
| A-Award | 2026-07-01 | 125,000 | $1.30 | $162.5K | ||
| A-Award | 2026-07-01 | 125,000 | $1.30 | $162.5K | ||
| Buy | 2026-03-12 | 15,000 | $1.63 | $24.4K | ||
| A-Award | 2026-03-05 | 3,250,000 | $1.84 | $5.98M | ||
| A-Award | 2026-03-05 | 1,050,000 | $1.84 | $1.93M | ||
| A-Award | 2026-03-05 | 900,000 | $1.84 | $1.66M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where LCTX earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the LCTX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Lineage Cell Therapeutics, Inc. (LCTX) is currently trading at $1.35, 55% below its 52-week high. The current dividend yield is 148.15% based on an annual payout of $2.00 per share.
LCTX (Lineage Cell Therapeutics, Inc.) — 148.15% Dividend Yield Analysis
Lineage Cell Therapeutics, Inc. (LCTX) is a healthcare stock currently trading at $1.35 with a dividend yield of 148.15%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (148.15%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.